New Recruiting Trial: A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
WHY IT MATTERS
This trial offers access to a potentially new treatment option for patients with myeloproliferative neoplasms who may have limited alternatives, particularly if they have specific subtypes targeted by this drug.
Prelude Therapeutics is testing a new drug called PRT12396 in people with certain blood cancers called myeloproliferative neoplasms. This is an early-stage study (Phase 1) to see if the drug is safe and how it works in the body. The study is now accepting patients and is expected to start in April 2026.
NCT ID: NCT07469891 Title: A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms Status: RECRUITING Phase: PHASE1 Sponsor: Prelude Therapeutics Start date: 2026-04-01 URL: https://clinicaltrials.gov/study/NCT07469891 Source: UniteRare clinical trials database
ASK YOUR DOCTOR
Ask your hematologist or oncologist if you might be eligible for this trial and whether PRT12396 could be appropriate for your specific myeloproliferative neoplasm diagnosis.